Intrathoracic extensive-stage small cell lung cancer: assessment of the benefit of thoracic and brain radiotherapy using the SEER database

Omar Mahmoud, Deukwoo Kwon, Brad Greenfield, Jean Wright, Michael A. Samuels

Research output: Contribution to journalArticle

Abstract

Background: Extensive-stage small cell lung cancer (ESCLC) includes metastatic disease and locally advanced disease confined to the thorax that cannot be encompassed in a typical radiation portal. We assessed and then compared the benefits of thoracic radiotherapy (TRT) and/or brain radiotherapy (BRT) on overall survival (OS) between the intrathoracic (T-ESCLC) and metastatic (M-ESCLC) groups using the Surveillance Epidemiology and End Results database. Methods: TRT and BRT data were available for 10150 patients treated from 1988−1997. The T-ESCLC group included 1774 patients. The Kaplan–Meier method was used to estimate OS and the proportional hazards model was used to estimate OS hazard ratios for prognostic factors including age, gender, race, tumor size, T/N stage, TRT, and BRT. Results: The 2-year OS for T-ESCLC was 7.8 % compared to 3 % in the M-ESCLC group (p <0.001). In the T-ESCLC group, TRT and BRT were delivered to 750 and 102 patients, respectively. The 2-year OS was 13 % in the TRT group compared to 4.1 % in the no-TRT group (p ≤ 0.001) and 22.5 % in the BRT group compared to 7 % in the no-BRT group (p <0.001). In the M-ESCLC group, TRT and BRT were delivered to 3093 and 1887 patients, respectively. The 2-year OS was 4.4 % in the TRT group compared to 2.8 % in the no-TRT group (p <0.001) and 4.3 % in the BRT compared to 2.6 % in the no-BRT group (p <0.001). Age, gender, TRT and BRT were significant OS prognostic factors in both groups. Conclusions: Our study suggests that T-ESCLC is a disease entity distinct from M-ESCLC. Prospective studies to determine whether TRT should be recommended for the thoracic-only subgroup are warranted.

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalInternational Journal of Clinical Oncology
DOIs
StateAccepted/In press - Jul 5 2016

Fingerprint

Small Cell Lung Carcinoma
Radiotherapy
Thorax
Databases
Brain
Survival

Keywords

  • Brain radiotherapy
  • Intrathoracic extensive stage
  • Small cell lung cancer
  • Survival outcome
  • Thoracic radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Surgery
  • Hematology

Cite this

Intrathoracic extensive-stage small cell lung cancer : assessment of the benefit of thoracic and brain radiotherapy using the SEER database. / Mahmoud, Omar; Kwon, Deukwoo; Greenfield, Brad; Wright, Jean; Samuels, Michael A.

In: International Journal of Clinical Oncology, 05.07.2016, p. 1-9.

Research output: Contribution to journalArticle

@article{0555c87351644de690aeb6b1543b1897,
title = "Intrathoracic extensive-stage small cell lung cancer: assessment of the benefit of thoracic and brain radiotherapy using the SEER database",
abstract = "Background: Extensive-stage small cell lung cancer (ESCLC) includes metastatic disease and locally advanced disease confined to the thorax that cannot be encompassed in a typical radiation portal. We assessed and then compared the benefits of thoracic radiotherapy (TRT) and/or brain radiotherapy (BRT) on overall survival (OS) between the intrathoracic (T-ESCLC) and metastatic (M-ESCLC) groups using the Surveillance Epidemiology and End Results database. Methods: TRT and BRT data were available for 10150 patients treated from 1988−1997. The T-ESCLC group included 1774 patients. The Kaplan–Meier method was used to estimate OS and the proportional hazards model was used to estimate OS hazard ratios for prognostic factors including age, gender, race, tumor size, T/N stage, TRT, and BRT. Results: The 2-year OS for T-ESCLC was 7.8 {\%} compared to 3 {\%} in the M-ESCLC group (p <0.001). In the T-ESCLC group, TRT and BRT were delivered to 750 and 102 patients, respectively. The 2-year OS was 13 {\%} in the TRT group compared to 4.1 {\%} in the no-TRT group (p ≤ 0.001) and 22.5 {\%} in the BRT group compared to 7 {\%} in the no-BRT group (p <0.001). In the M-ESCLC group, TRT and BRT were delivered to 3093 and 1887 patients, respectively. The 2-year OS was 4.4 {\%} in the TRT group compared to 2.8 {\%} in the no-TRT group (p <0.001) and 4.3 {\%} in the BRT compared to 2.6 {\%} in the no-BRT group (p <0.001). Age, gender, TRT and BRT were significant OS prognostic factors in both groups. Conclusions: Our study suggests that T-ESCLC is a disease entity distinct from M-ESCLC. Prospective studies to determine whether TRT should be recommended for the thoracic-only subgroup are warranted.",
keywords = "Brain radiotherapy, Intrathoracic extensive stage, Small cell lung cancer, Survival outcome, Thoracic radiotherapy",
author = "Omar Mahmoud and Deukwoo Kwon and Brad Greenfield and Jean Wright and Samuels, {Michael A.}",
year = "2016",
month = "7",
day = "5",
doi = "10.1007/s10147-016-1011-z",
language = "English (US)",
pages = "1--9",
journal = "International Journal of Clinical Oncology",
issn = "1341-9625",
publisher = "Springer Japan",

}

TY - JOUR

T1 - Intrathoracic extensive-stage small cell lung cancer

T2 - assessment of the benefit of thoracic and brain radiotherapy using the SEER database

AU - Mahmoud, Omar

AU - Kwon, Deukwoo

AU - Greenfield, Brad

AU - Wright, Jean

AU - Samuels, Michael A.

PY - 2016/7/5

Y1 - 2016/7/5

N2 - Background: Extensive-stage small cell lung cancer (ESCLC) includes metastatic disease and locally advanced disease confined to the thorax that cannot be encompassed in a typical radiation portal. We assessed and then compared the benefits of thoracic radiotherapy (TRT) and/or brain radiotherapy (BRT) on overall survival (OS) between the intrathoracic (T-ESCLC) and metastatic (M-ESCLC) groups using the Surveillance Epidemiology and End Results database. Methods: TRT and BRT data were available for 10150 patients treated from 1988−1997. The T-ESCLC group included 1774 patients. The Kaplan–Meier method was used to estimate OS and the proportional hazards model was used to estimate OS hazard ratios for prognostic factors including age, gender, race, tumor size, T/N stage, TRT, and BRT. Results: The 2-year OS for T-ESCLC was 7.8 % compared to 3 % in the M-ESCLC group (p <0.001). In the T-ESCLC group, TRT and BRT were delivered to 750 and 102 patients, respectively. The 2-year OS was 13 % in the TRT group compared to 4.1 % in the no-TRT group (p ≤ 0.001) and 22.5 % in the BRT group compared to 7 % in the no-BRT group (p <0.001). In the M-ESCLC group, TRT and BRT were delivered to 3093 and 1887 patients, respectively. The 2-year OS was 4.4 % in the TRT group compared to 2.8 % in the no-TRT group (p <0.001) and 4.3 % in the BRT compared to 2.6 % in the no-BRT group (p <0.001). Age, gender, TRT and BRT were significant OS prognostic factors in both groups. Conclusions: Our study suggests that T-ESCLC is a disease entity distinct from M-ESCLC. Prospective studies to determine whether TRT should be recommended for the thoracic-only subgroup are warranted.

AB - Background: Extensive-stage small cell lung cancer (ESCLC) includes metastatic disease and locally advanced disease confined to the thorax that cannot be encompassed in a typical radiation portal. We assessed and then compared the benefits of thoracic radiotherapy (TRT) and/or brain radiotherapy (BRT) on overall survival (OS) between the intrathoracic (T-ESCLC) and metastatic (M-ESCLC) groups using the Surveillance Epidemiology and End Results database. Methods: TRT and BRT data were available for 10150 patients treated from 1988−1997. The T-ESCLC group included 1774 patients. The Kaplan–Meier method was used to estimate OS and the proportional hazards model was used to estimate OS hazard ratios for prognostic factors including age, gender, race, tumor size, T/N stage, TRT, and BRT. Results: The 2-year OS for T-ESCLC was 7.8 % compared to 3 % in the M-ESCLC group (p <0.001). In the T-ESCLC group, TRT and BRT were delivered to 750 and 102 patients, respectively. The 2-year OS was 13 % in the TRT group compared to 4.1 % in the no-TRT group (p ≤ 0.001) and 22.5 % in the BRT group compared to 7 % in the no-BRT group (p <0.001). In the M-ESCLC group, TRT and BRT were delivered to 3093 and 1887 patients, respectively. The 2-year OS was 4.4 % in the TRT group compared to 2.8 % in the no-TRT group (p <0.001) and 4.3 % in the BRT compared to 2.6 % in the no-BRT group (p <0.001). Age, gender, TRT and BRT were significant OS prognostic factors in both groups. Conclusions: Our study suggests that T-ESCLC is a disease entity distinct from M-ESCLC. Prospective studies to determine whether TRT should be recommended for the thoracic-only subgroup are warranted.

KW - Brain radiotherapy

KW - Intrathoracic extensive stage

KW - Small cell lung cancer

KW - Survival outcome

KW - Thoracic radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=84977098527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977098527&partnerID=8YFLogxK

U2 - 10.1007/s10147-016-1011-z

DO - 10.1007/s10147-016-1011-z

M3 - Article

C2 - 27380168

AN - SCOPUS:84977098527

SP - 1

EP - 9

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

ER -